Tissue transglutaminase (TG2), an enzyme involved in cell proliferation, differentiation and apoptosis is overexpressed in ovarian carcinomas, where it modulates epithelial-to-mesenchymal transition (EMT) and promotes metastasis. Its regulation in ovarian cancer (OC) remains unexplored. Here, we show that transforming growth factor (TGF)-b, a cytokine involved in tumor dissemination is abundantly secreted in the OC microenvironment and induces TG2 expression and enzymatic activity. This is mediated at transcriptional level by SMADs and by TGFb-activated kinase 1-mediated activation of the nuclear factor-jB complex. TGF-b-stimulated OC cells aggregate as spheroids, which enable peritoneal dissemination. We show that TGF-b-induced TG2 regulates EMT, formation of spheroids and OC metastasis. TG2 knock-down in OC cells decreases the number of cells harboring a cancer stem cell phenotype (CD44 þ /CD117 þ ). Furthermore, CD44 þ /CD117 þ cells isolated from human ovarian tumors express high levels of TG2. In summary, TGFb-induced TG2 enhances ovarian tumor metastasis by inducing EMT and a cancer stem cell phenotype.
Introduction
Tissue transglutaminase (TG2), an enzyme overexpressed in epithelial malignancies (Mann et al., 2006; Satpathy et al., 2007) , participates in Ca þ þ -dependent protein post-translational modifications and cross-linking by transferring acyl groups between glutamine and lysine residues (Pincus and Waelsch, 1968) . We reported that TG2 is upregulated in ovarian tumors Satpathy et al., 2007) and has a critical role in the process of epithelial-to-mesenchymal transition (EMT), a hallmark of cancer progression. This translates into increased ovarian cancer (OC) cell invasiveness ) and intraperitoneal tumor dissemination (Satpathy et al., 2007; Shao et al., 2009) . The involvement of TG2 in EMT and tumor dissemination led to the hypothesis that its expression and function are induced by transforming growth factor (TGF)-b, a key regulator of metastasis.
TGF-b is a poly-peptide that potently inhibits the growth of epithelial cells. The active form binds to one of two types of receptors, causing receptor phosphorylation (Dennis and Rifkin, 1991) . Intra-cellular signaling proceeds through receptor-activated SMADs (R-SMAD) that form a complex with SMAD4, which then translocates into the nucleus (Massague, 1996) . The activated R-SMAD/SMAD4 complex recruits transcriptional co-activators or co-repressors and binds to DNA through SMAD-binding elements containing the 4-bp motif 5 0 -AGAC-3 0 (Zawel et al., 1998) . Given the low specificity of this SMAD-binding element, regulation of target genes depends on recruitment of activators or repressors, which are cell type-specific. In addition, TGF-b modulates gene transcription through SMADindependent mechanisms (Derynck and Zhang, 2003) , such as the pathways regulated by the TGF-b-activated kinase 1 (TAK1) (Yamaguchi et al., 1995) . Such SMAD-independent mechanisms are engaged in TGFb-modulated regulation of fibronectin (FN) (Hocevar et al., 2005) and collagen (Qiao et al., 2005) .
In cancer, TGF-b exerts dual roles, as tumor suppressor through inhibition of epithelial cell growth and as tumor promoter by enhancement of cell invasion and metastasis (Akhurst and Derynck, 2001 ). Overexpression of TGF-b was observed in tumors in association with metastasis (Kopp et al., 1995) or increased cell invasiveness (Tobin et al., 2002; Dumont et al., 2003) . An important function related to promotion of metastasis is the phenomenon of EMT. This is characterized by break-down of cell junctions and loss of cell polarity, rendering epithelial cells more motile and invasive (Thiery, 2002) . EMT has important roles during development (Yamashita et al., 2004) and in cancer, where it initiates metastasis. A critical step of EMT is the loss of type I cadherins that maintain stable cell-cell contacts (Perl et al., 1998) . Downregula-tion of E-cadherin is a critical disruptor of epithelial homeostasis, leading to the adoption of a mesenchymal behavior (Nagafuchi et al., 1987; Thiery, 2002) . Loss of E-cadherin is modulated by transcriptional repressors like Snail, Slug, Zeb 1/2 and the basic helix-loop-helix factors E47 and Twist (Moreno-Bueno et al., 2006) . Activation of SMADs by TGF-b recruits Snail (Vincent et al., 2009) , Zeb (Comijn et al., 2001) or Twist (Thuault et al., 2006) , which repress E-cadherin.
Our previous observations regarding TG2's role in metastasis led to the hypothesis that the enzyme is regulated by TGF-b and is necessary for TGFb-induced EMT. We show here that TGF-b is secreted in the ovarian tumor microenvironment inducing the expression and function of TG2 primarily through a SMADdependent mechanism. SD208, a TGF-b receptor I inhibitor blocked EMT and metastasis in xenografts derived from cells lacking TG2, but less significantly in tumors expressing constitutively TG2. OC cells transitioned to a mesenchymal phenotype form spheroids, which allow dissemination in the peritoneal cavity. Spheroids are enriched in CD44 þ /CD117 þ cells, phenotype recognized as a signature for OC initiating cells (OCIC) (Zhang et al., 2008) . TG2 knock-down prevented TGF-b-induced EMT, decreased the number of CD44 þ /CD117 þ cells and blocked spheroid formation by OC cells. TG2 expression levels are increased in CD44 þ /CD117 þ cells isolated from human ovarian tumors. The results support that TGF-b-induced TG2 regulates EMT, metastasis and spheroid formation by OC cells.
Results

TGF-b1 induces TG2 expression and function in OC cells
Having previously observed that TG2 is overexpressed in OC cells in association with a metastatic phenotype (Satpathy et al., 2007 , we tested whether TGF-b1 induces its expression. Increased TG2 expression was observed in SKOV3 cells, immortalized C272/hTert/E7 cells and primary OC cells (OVCA) treated with TGF-b1 for 24-48 h (Figure 1a , P ¼ 0.01). TGF-b1 induced TG2 expression in other OC cell lines (Hey, IGROV1; Supplementary Figure 1b) . Levels of relative TG2 expression in OC cell lines are shown in Supplementary Figure  1a . In contrast, TGF-b1 augmented only modestly TG2 expression in normal ovarian surface epithelial cells (NOSE-907 and 911), or in the non-transformed mesothelial cells LP9 derived from human peritoneum (Figure 1b) . OC cell lines and non-transformed NOSE and LP9 cells express TGF-b1 receptors I and II and TAK1 at similar levels. However, SMAD2/3 expression levels were slightly lower in NOSE and LP9 cells compared with OC cells, while the inhibitory protein SMAD 7 was expressed in NOSE and LP9 cells, but not in all OC cell lines (Supplementary Figure 1b) . TGF-b1's effects on TG2 in OC cells occur at transcription level as demonstrated by quantitative reverse transcriptase-PCR ( Figure 1c ) and TG2 reporter assay (Figure 1d) . A neutralizing antibody to TGF-b blocked TG2's induction by the cytokine (Supplementary Figure 1c ).
The effects of TGF-b1 on TG2 expression were more pronounced when cells were cultured on FN (Supplementary Figure 1d ), therefore subsequent experiments used FN-coated plates. Dose-response experiments demonstrated that the effects of TGF-b1 on TG2 expression occur from concentrations of 0.5-5 ng/ml of TGF-b1 (Supplementary Figure 1e) , ranging within physiological limits. The enzymatic function of TG2 was also induced by TGF-b1, as measured by amine incorporation into total cellular proteins (Zhang et al., 1998) . Increased TG2 activity was observed in OC cells (Hey and OVCA#16), but not in non-transformed LP9 or NOSE cells (Supplementary Figure 2) . This increase in enzymatic function likely reflected TGF-b induction of TG2 expression in OC cells, but not in non-transformed cells.
TGF-b1 is secreted by OC cells
Secretion of TGF-b1 by OC cells was quantified by enzyme-linked immunosorbent assay in serum-free conditioned media from OC cell lines or primary cells (n ¼ 12) or in media conditioned by NOSE (n ¼ 3). Higher levels of TGF-b1 were secreted by OC cells (1203±271 pg/ml) compared with NOSE (71±23 pg/ml; P ¼ 0.002, Figure 2a ), suggesting an association between TGF-b secretion and the malignant phenotype. As OC progression leads to accumulation of peritoneal fluid rich in secreted proteins, we measured TGF-b1 secretion in malignant ascites (n ¼ 10). The cytokine was secreted in the peritoneal OC fluid at higher levels (1719±275 pg/ml) compared with non-malignant effusions (387 ± 341 pg/ml; n ¼ 3, P ¼ 0.004, Figure 2b ).
To test whether secreted TGF-b1 alters TG2 expression, we evaluated the effects of conditioned media from OC cells on TG2 expression. Significant increase in TG2 mRNA level was induced by media conditioned by OC cells (threefold, Figure 2c ), comparable to the effects of recombinant TGF-b1. Pre-treatment with a TGF-b receptor kinase inhibitor led to partial decrease in TG2 induction (P ¼ 0.04), suggesting the effects of the conditioned media are caused by secreted TGF-b. However, the incomplete effect of the inhibitor supports that OC cells secrete factors other than TGF-b that regulate TG2. Such secreted factors may include epidermal growth factor (EGF), tumor necrosis factora or platelet-derived growth factor (PDGF) that are detectable in OC ascites and could alter TG2 expression. Similarly, treatment of serum-starved OC cells with the TGF-b inhibitor diminished the basal TG2 expression level (Figure 2c) , consistent with the concept that an autocrine TGF-b loop is functional in OC cells.
SMADs mediate TG2 regulation by TGF-b
Activation of TGF-b1-mediated signaling in OC cells was assessed by measuring the phosphorylation of SMAD2/3 and TAK1, the main transducers of the cytokine's signal. Both pathways were phosphorylated within 15 min and remained activated for up to 24 h after TGF-b1 treatment in SKOV3 cells (Figure 3a, left) . Similar results were obtained in C272/hTERT/E7 cells (not shown). Activation of TGF-b1 signaling was also measured in non-transformed NOSE and LP9 cells (Figure 3a , right). SMAD2/3 was modestly activated by TGF-b in these cells and TAK1 phosphorylation was not detectable (not shown).
To test which of the elements of the TGF-b1 pathway are important to TG2's induction, we utilized small interfering RNA (siRNA) targeting the main elements of the cascade (SMAD2/3, TAK1, c-Jun N-terminal kinase (JNK)2, p38 and p65, the active subunit of the nuclear factor (NF)-kB complex), first focusing on the role of SMADs. Knock-down of the SMAD2/3 complex prevented the induction of TG2 by TGF-b1 both at protein and mRNA level (Figure 3b ), suggesting its involvement in TG2 regulation by TGF-b1. A bioinformatic search using PROMO (http://alggen.lsi.upc.es/cgi-bin/ promo_v3/promo/promoinit.cgi?dirDB ¼ TF_8.3) identified several putative SMAD-binding elements in the À191 to À840 TG2 promoter region. Binding of SMAD4 and of pSMAD3 to the TG2 promoter after TGF-b1 stimulation was demonstrated by chromatin immunoprecipitation utilizing primers encompassing the À269 to À479 TG2 promoter fragment (Figure 3c and Supplementary Figure 3a) , the region where two SMAD-binding elements were predicted. Furthermore, we evaluated TG2 expression and SMAD3 activation in 30 human ovarian tumors on a tissue microarray by immunohistochemistry noting significant correlation between TG2 and pSMAD3 staining (P ¼ 0.01, odds ratio 13.6, Figure 3d and Supplementary Table 1 ).
The role of TAK1 and NF-kB in TG2 regulation by TGF-b1 Although SMADs activate gene transcription directly by binding to chromatin, TAK1 acts indirectly by activating other targets. Depending on the cellular context, TAK1 may activate p38, the stress-activated kinase JNK, or the NF-kB complex (Hanafusa et al., 1999; Abendstein et al., 2000; Derynck and Zhang, 2003) . Therefore, we measured the activation status of these known TAK1 targets in response to TGF-b1. Phosphorylation of JNK1/2 was noted at late timepoints (16-24 h) after TGF-b1 treatment, while p38 was not detectably phosphorylated ( Figure 4a ). In contrast, the expression level of inhibitor of nuclear factor-kB, a (IkBa), the inhibitory unit for the NF-kB complex was reduced within 1-3 h after TGF-b1 treatment (Figure 4b, upper panel) . This suggested the NF-kB complex as a potential transducer of TGF-b-stimulated TAK1 activity in OC cells. Increased NF-kB activity TAK1 knock-down by siRNA prevented TG2's induction by TGF-b at protein and mRNA level ( Figure 4c ). To identify which pathway downstream of TAK1 is involved in TG2 regulation we knocked-down JNK2, p38 and p65. Knock-down of p38 and JNK2 did not prevent TG2's induction by TGF-b1, at protein and mRNA levels (Figures 4d and e), suggesting that these pathways are not involved in TG2 regulation by TGFb1. Further, siRNA targeting JNK2, p38, and to lesser extent TAK1 caused a small increase in the basal level of TG2 mRNA, suggesting these pathways exert an inhibitory effect on TG2. In contrast, knock-down of p65, the other TAK1 target, blocked TGF-b1-induced TG2, supporting that the NF-kB complex, activated downstream of TAK1, regulates TG2 ( Figure 4f ). In addition, overexpression of p65 potently induced TG2 mRNA expression level, demonstrating the additional role of this pathway in TG2's transcriptional regulation in OC cells (Figure 4g ).
TGF-b-regulated TG2 expression is significant to EMT and OC metastasis
To test the significance of TGF-b-induced TG2 expression, we assessed its effects on the morphology and functions of OC cells. TGF-b1-treated SKOV3 cells underwent characteristic morphological changes of EMT, from a compact shape to an elongated, dispersed phenotype evident 24-72 h after treatment ( Figure 5a ). The mesenchymal phenotype was confirmed by quantifying the expression of EMT markers, E-cadherin, N-cadherin, and of the transcriptional regulator Zeb1. Decrease in E-cadherin expression, associated with increased expression of N-cadherin, Zeb1 and TG2 were observed in TGF-b1-treated SKOV3 cells (Figure 5b ), confirming that TGF-b1-induced EMT. To test the significance of TG2 to EMT and metastasis, we utilized SKOV3 cells stably transfected with an antisense construct (AS-TG2) or the empty vector pcDNA3.1 (Figure 5c , left). Induction of EMT by TGF-b1, as assessed by cell morphology or quantification of EMT markers, was prevented in SKOV3-ASTG2 compared with control cells, supporting TG2's role downstream of TGF-b (Supplementary Figures 3b and  c) . Further, the TGF-b receptor I serine threonine kinase inhibitor, SD208 (Mohammad et al., 2011) blocked TGF-b-induced SMAD2/3 activation and TG2 induction in SKOV3-ASTG2 and control cells (Figure 5c , right). Treatment with SD208 also increased E-cadherin expression in SKOV3-ASTG2 cells, to a greater degree than in control cells. In vivo, in an intraperitoneal (i.p.) xenograft model in nude mice, SD-208 blocked almost completely formation of peritoneal metastases derived from SKOV3-ASTG2 cells (16 vs 142, P ¼ 0.006), as compared with metastases derived from SKOV3-pCDNA3.1 cells (278 vs 383, P ¼ 0.08, Figure 5d ). As the i.p. model yields widely disseminated milliary metastases, large tumor masses were not generated and no appreciable effect of SD208 on tumor volume was recorded (not shown). This corresponded to almost undetectable TG2 expression levels in AS-TG2 derived tumors treated with SD-208. TG2 expression level was only modestly decreased in control tumors from animals treated with the inhibitor (Figure 5e ). Significant difference between number of peritoneal To understand how TG2 participates in EMT induction, we used an OC cell model that does not express endogenously TG2 (OV90 cells) and stably transduced these cells with wild-type TG2 and with a TG2 fragment corresponding to the 140 amino acid N-terminus fragment that contains the region binding FN (tTG1-140) (Hang et al., 2005) . This fragment lacks the enzymatic core and the fragment-mediating GTP-ase activity (Figure 6a ). Quantification of EMT markers at protein and mRNA levels demonstrates that both wildtype TG2 and tTG1-140 induce downregulation of E-cadherin and upregulation of Zeb1 (Figures 6a and b) . Similarly, both wild-type TG2 and tTG1-140-induced cell invasion through matrigel consistent with a mesenchymal phenotype (Figure 6c ). These data suggest that the FN-binding domain of TG2, lacking both enzymatic and GTP-ase function is sufficient to induce EMT. Interestingly, it has been recently shown that this fragment is essential for TG2's secretion in the ECM and interaction with the matrix (Chou et al., 2011) . Indeed expression of both full length TG2 and tTG1-140 Tissue transglutaminase L Cao et al increases cell adhesion to FN, as previously reported (Akimov and Belkin, 2001; Hang et al., 2005) (Figure 6d ). These data suggest that TG2's role facilitating cell interaction with the ECM is implicated in EMT.
Spheroid formation induced by TGF-b An important step in the process of OC dissemination is the formation of cellular spheroids. These allow cancer cells to float in the abdominal cavity as multicellular aggregates, protecting them from environmental stresses and facilitating invasion into the mesothelium (Sodek et al., 2009) . We therefore investigated whether TGF-b1 enhanced OC spheroid formation by inducing TG2. Increased size and number of spheroids were induced by TGF-b1 in IGROV 1 cells (Figure 7a , P ¼ 0.05, left). TGF-b1 also increased the size of spheroids formed by cells disaggregated from human ovarian tumors (Figure 7a, right) . To test whether induction of TG2 by TGF-b1 has a role, we measured the effects of TG2 knock-down on spheroid formation. Transduction of short hairpin Prior studies indicated that cancer cells with stem cell phenotype aggregate as spheroids when cultured under low adherence conditions in the absence of differentiating factors (Al-Hajj and Clarke, 2004; Zhang et al., 2008) . Further, cancer cells cultured as spheroids are enriched in cells with stem phenotype (Dontu et al., 2003) . We therefore quantified the percentage of cells harboring the OCIC phenotype within spheroids and tested the effects of TGF-b1 on this cell population. We used CD44 and CD117 as the cell surface markers, Tissue transglutaminase L Cao et al based on the demonstration that cells double staining for these markers display the functional characteristics of stem cells, including the ability to differentiate, to generate tumors in mice and to be chemoresistant (Zhang et al., 2008) . We observed that as compared with monolayer, IGROV1 spheroids were enriched in CD44 þ (35 vs 3%) and CD44 þ /CD117 þ (2.5 vs 1%) cell population (Figure 7d ). TGF-b1 treatment of IGROV1 cells enriched the CD44 þ (36 vs 23%) and CD44 þ /CD117 þ cell subpopulations (2.5 vs 1.4%, Supplementary Figure 4a) .
We investigated next whether TGF-b1-inducible TG2 alters the OCIC cell population by quantifying the percentage of CD44 þ /CD117 þ cells in SKOV3 cells ± TG2. Significantly fewer CD44 þ /CD117 þ cells were identified in SKOV3-AS-TG2 (0.7%) compared with control cells (7.8%; Figure 8a ), suggesting that TG2 is important to this phenotype. The expression levels of Nanog, Oct3/4 and Sox-2, stem cell-specific transcription factors were measured in cells ±TG2. Increased levels of Nanog and Sox-2 were noted in SKOV3-control and OV90-TG2 cells compared with SKOV3-ASTG2 and OV90-vector, respectively (Figure 8b) . Oct 3/4 expression level was increased in OV90-TG2 compared with control cells, but was not different in SKOV3 ±TG2. TGF-b-induced threefold increase in the number of CD44 þ /CD117 þ in SKOV3-pCDNA3.1 cells, but not in SKOV3-ASTG2 cells (Supplementary Figure 4b) . Collectively, these data support the concept that TG2 expression level correlates with TGF-b-inducible stem cell phenotype.
To demonstrate relevance to human OC, we isolated CD44 þ /CD117 þ cells from human tumors and measured TG2 mRNA expression levels in double staining cells, un-fragmented tumor, ascites, and double-negative cells. TG2 expression level was increased 410-fold in CD44 þ /CD117 þ cells compared with whole tumor or cells isolated from ascites (Figure 8c , upper panel, Po0.001) or to CD44-/CD117-cells dissociated and sorted from ovarian tumors (P ¼ 0.002; n ¼ 3, Figure 7c , lower panel). These data support that TGF-b-regulated TG2 induces EMT, which is important to cell aggregation as spheroids, promotion of metastasis and maintenance of OCICs, as illustrated in the model in Figure 8d .
Discussion
We provide here the first evidence that TGF-b secreted in the OC milieu regulates the expression and function of TG2 primarily through activation of the canonical SMAD pathway. TG2 is not induced by TGF-b in normal surface ovarian epithelial cells coinciding with more modest activation of the SMAD2/3 complex. TG2 induction by TGF-b1 in OC cells contributes to EMT and the aggregation of OC cells as spheroids, which are critical and sequential steps in the development of peritoneal metastasis of ovarian tumors and have a role in the homeostasis of OCICs. We show for the first time that TGF-b-inducible TG2 has a role in the maintenance of the OCIC phenotype of cancer cells. A TGF- b inhibitor blocked peritoneal metastasis formation in a manner consistent with suppression of TG2 expression levels. We propose a model whereby TGFb-inducible TG2 modulates EMT, metastasis and OCIC homeostasis. These data contribute to a better understanding of the mechanisms of OC metastasis modulated by TG2. The implications of our study are several. First, we demonstrate that activation of TGF-b signaling in OC cells induces the expression and function of TG2, an enzyme we previously linked to OC metastasis (Satpathy et al., 2007; Shao et al., 2009) . The specificity of TGF-b's effect is demonstrated as TG2 induction is blocked by a neutralizing antibody or a TGF-b receptor kinase inhibitor. We show that TGF-b is abundantly secreted in the peritoneal milieu through autocrine and paracrine mechanisms. The existence of a functional TGF-b signaling pathway in OC has been documented in prior studies (Cardillo et al., 1997; Baldwin et al., 2003; Dowdy et al., 2003) , the cytokine and its receptors being expressed in over 50% of ovarian tumors (Bartlett et al., 1997; Bristow et al., 1999; Abendstein et al., 2000) . Loss of growth inhibitory effects of TGF-b in OC cells has been attributed in a minority of cases to TGF-b receptor I and II inactivating mutations (Lynch et al., 1998; Chen et al., 2001) or to alterations of cell signaling downstream of SMADs Hu et al., 2000; Baldwin et al., 2003) . Like in other malignancies, TGF-b has been linked to increased invasiveness by regulating the expression of proteins involved in metastasis (Rodriguez et al., 2001; Wakahara et al., 2004) . Its effects on TG2 illustrated here are likely to contribute to invasion of stroma and OC metastasis, as the enzyme has been strongly implicated in both events (Satpathy et al., 2007 ). Interestingly, we observed that TGFb did not induce TG2 expression or enzymatic activity in non-transformed NOSE and LP9 cells. Like OC cells, these epithelial cells express type I and II TGF-b1 receptors and the other elements of the signaling cascade, as previously reported (Nilsson et al., 2001; Baldwin et al., 2003) . It is possible that attenuated SMAD and TAK activation in NOSE cells may be implicated in the decreased response of TG2 to TGF-b1.
Second, we point to the canonical pathway as the principal mechanism regulating TG2 and demonstrate direct binding of pSMAD3 to the TG2 promoter in response to TGF-b stimulation. TG2 expression and SMAD activation were correlated in human ovarian tumors. However, TGF-b also engages the non-canonical pathway in OC cells, through activation of TAK1. 
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Cooperation and interaction between SMADs and NFkB in transcriptional regulation for other gene targets have been previously recorded (Lopez-Rovira et al., 2000) . By using specific silencing or overexpression of TAK1 targets, we demonstrate that the main TG2 regulator in the non-canonical pathway is the NF-kB complex. As TG2 is a known inducer of NF-KB activity in OC (Cao et al., 2008) and in other cancer cells (Mann et al., 2006) , it appears that a forward positive feed loop exists between the enzyme and NF-kB.
Third, we show that TGF-b's effects on TG2 have a role in the induction of EMT, OC cell spheroid formation and metastasis. TG2 expression levels correlated with peritoneal OC dissemination in an i.p. ovarian xenograft model and treatment with a TGF-b receptor inhibitor abrogated peritoneal metastasis in a manner directly correlated with TG2 expression levels. Interestingly, we show that the FNbinding domain of TG2 is sufficient to induce EMT. Future studies will focus on TG2's role in cell-matrix interactions and the regulation of EMT machinery, as well as on fully evaluating the potential additional roles of the protein (catalytic, GTPase) in this process.
Finally, we show that TGF-b increases the number of cells with an OCIC phenotype and that TG2 knock-down decreases the percentage of OCIC cells. These observations were first made by using OC cell lines and subsequently validated in cells derived from human ovarian tumors. On the basis of a previous report demonstrating that CD44 þ / (Zhang et al., 2008) , we chose this as the OCIC phenotype studied here. Our data show that CD44 þ /CD117 þ cells dissociated from human ovarian tumors express higher levels of TG2 and that knock-down of TG2 decreases the percentage of CD44 þ /CD117 þ cells and spheroid formation by OC cells. As EMT is a required step in the generation and persistence of cancer stem cells (Mani et al., 2008) , we attribute these findings to TG2's function of inducing and maintaining a mesenchymal phenotype. Along with others, we previously demonstrated that TG2 expression levels correlate with chemoresistance (Mehta et al., 2004; Cao et al., 2008) , a characteristic of stem cells (Szotek et al., 2006) , further supporting the link between TG2 and the OCIC phenotype. In summary, the current results provide strong evidence for the involvement of TGF-b in OC invasion and tumor progression through regulation of TG2. We demonstrate that TGF-b-induced TG2 is involved in EMT, metastasis, and growth of OC cells as spheroids. These results point to potential therapeutic interventions targeting TG2 or TGF-b signaling to interrupt OC tumor progression.
Materials and methods
Chemicals and reagents
Human TGF-b1 was from R&D Systems (Minneapolis, MN, USA), the TGF-b receptor I kinase inhibitor was from Calbiochem (La Jolla, CA, USA) and SD-208 was from Scios Inc. (Fremont, CA, USA) (Mohammad et al., 2011) . The antibody against TG2 was from Neomarkers (Fremont, CA, USA), antibodies against phospho-Smad2, phospho-TAK1, phospho-p38, phospho-JNK1/2, phospho-Akt, Smad2/3, TAK1, p38, JNK1/2, N-cadherin, and E-cadherin were from Cell Signaling Technology (Danvers, MA, USA), Zeb1, TGF-b1 receptor I and II, IkBa and Smad7 from Santa Cruz Biotechnology (Santa Cruz, CA, USA), neutralizing TGF-b antibody for R&D (MAB1835), vimentin from Sigma-Aldrich (St Louis, MO, USA) and glyceraldehyde 3-phosphate dehydrogenase from Biodesign International (Saco, ME, USA). Fluorescein isothiocyanate-conjugated anti-CD44 and antigen-presenting cell-conjugated anti-CD117 were from BD Biosciences (San Jose, CA, USA).
Cell lines and primary cultures
Human OC cell lines SKOV 3 , Hey, OV90 and IGROV1 were from the American Type Culture Collection (ATCC), Manassas, VA, USA. The mesothelial cell line LP9 was provided by Dr Y Xu, normal ovarian surface epithelial (NOSE#907, #911) cells by Dr R Bigsby, being established from normal ovaries, as described ). The immortalized cell line C272/hTert/E7 was previously described (Gillan et al., 2002) . OVCA cells are primary cultures obtained from OC malignant ascites or from disaggregated human ovarian tumors. All cells were cultured in media containing 1:1 MCDB 105 (Sigma-Aldrich) and M199 (Cellgro, Herndon, VA, USA) supplemented with 10% fetal bovine serum. Treatment with TGF-b1 was continuous for the timeline specified.
Transfection
Stable knock-down of TG2 was achieved by transfection of an antisense construct (AS-TG2) described previously (Satpathy et al., 2007) or by transducing lentiviral particles containing short hairpin RNA targeting TG2 (Sigma-Aldrich). Wild-type TG2 and tTG1-140 overexpression used the retroviral system pQCXIP in OV90 cells as described followed by puromycin selection of polyclonal cell populations . The tTG1-140 construct was from A Belkin (Hang et al., 2005) and the p65 construct from Dr H Nakshatri. siRNAs targeting Smad2/3 (Cell Signaling), p38 (Cell Signaling), TAK1, JNK2, p65 or scrambled siRNA (Dharmacon, Lafayette, CO, USA) were transiently transfected by using DreamFect (OZ Biosciences, Marseille, France).
Human ovarian tumors and ascites specimens Studies using human specimens were approved by the IU Institutional Review Board, specimens being de-identified. Tumors were obtained at debulking surgery and the diagnosis of OC was verified. All tumors were serous papillary. Ten samples of OC malignant ascites and three samples of inflammatory parapneumonic pleural fluid were obtained from the IU Tissue Bank.
Isolation of OC stem cells
Fresh tumor samples were minced and digested in serum-free Dulbecco's modified Eagle's medium/F12 media (Invitrogen, Carlsbad, CA, USA) containing collagenase and hyaluronidase (Sigma-Aldrich). The resulting single cell suspension was filtered through a 40-mm cell strainer and red blood cells were removed with Histopaque-1077 (Sigma-Aldrich). Cells dissociated from tumors or OC cell lines were labeled with fluorescein isothiocyanate-conjugated anti-CD44 and antigen-presenting cell-conjugated anti-CD117 and sorted using a FACS-Aria flow cytometer (BD Biosciences, San Jose, CA, USA). Quantification of the CD44 þ /CD117 þ population was performed independently more than three times in each cell type studied.
Spheroid cultures
To induce formation of cellular spheroids, OC cells were seeded at a concentration of 1000 cells/ml in serum-free Dulbecco's modified Eagle's medium/F12 supplemented with insulin, epidermal growth factor, basic fibroblast growth factor and bovine serum albumin in ultra-low attachment plates (Corning, Corning, NY, USA) and allowed to form spheroids over 10-14 days, as previously described (Zhang et al., 2008) .
Matrigel invasion assay
Invasion assay was performed by using two-dimensional and three-dimensional cell culture in a matrigel matrix (BDBiosciences, Palo Alto, CA, USA, see Supplementary Material).
Solid phase adhesion
Equal numbers of cells labeled with calcein acetoxymethylester were seeded into 96-well plates coated with FN (5 mg/ml) and blocked with bovine serum albumin (1% w/v). After 1 h of incubation at 37 1C, the plate was immersed into phosphatebuffered saline containing 1 mm MgCl 2 to remove nonadherent cells. The number of adherent cells was measured in a fluorescence plate reader (Applied Biosystems, Foster City, CA, USA) at an excitation wavelength of 485 nm. All experiments were performed in quadruplicate.
Immunoblotting Cells or homogenized frozen tumors were lysed into RIPA buffer containing protease inhibitors and Na 3 VO 4 . Protein Tissue transglutaminase L Cao et al concentration was measured by the Bradford method and equal amounts of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidine fluoride membranes. Membranes were blocked, probed with primary, then with corresponding HRP-labeled secondary antibodies. Antigen-antibody complexes were visualized using enhanced chemiluminescence.
Quantitative reverse transcriptase-PCR RNA extracted with RNA STAT-60 reagent (Tel-Test, Inc., Friendswood, TX, USA) was reverse-transcribed using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). FastStart TaqMan Probe Master (Roche, Indianapolis, IN, USA) was used for quantitative reverse transcriptase-PCR on an ABI Prism 7900 platform (Applied Biosystems), using specific primers and probes (Supplementary Material). Relative mRNA expression levels were normalized to glyceraldehyde 3-phosphate dehydrogenase.
Gene reporter assay A Dual-Luciferase Assay (Promega, Madison, WI, USA) was performed to quantify TG2 and NF-kB promoter activities. In brief, cells were co-transfected with the experimental reporter plasmid and control renilla plasmid at 10:1 ratio. Luminescence was measured with a TD-20/20 luminometer and normalized to renilla.
In situ TG2 activity assay The assay was performed to determine the incorporation of 5-(biotinamido) pentylamine (Pierce, Rockford, IL, USA) into proteins, as previously described (see Supplementary Material) (Zhang et al., 1998) .
Enzyme-linked immunosorbent assay
An enzyme-linked immunosorbent assay assay (R&D) measured TGF-b1 concentrations in the conditioned media of OC (n ¼ 12) or NOSE cells (n ¼ 3) and in malignant OC ascites (n ¼ 10) or pleural fluid from parapneumonic effusions (n ¼ 3), following the manufacturer's protocol.
Immunohistochemistry
A tissue microarray from Pantomics (San Francisco, CA, USA) including 30 human epithelial ovarian tumors arrayed in duplicates was immunostained for pSMAD3 and TG2 (see Supplementary Material).
Chromatin immunoprecipitation
To detect the interaction between SMADs and the TG2 promoter, chromatin immunoprecipitation assay was performed by using a kit from Millipore (Billerica, MA, USA), SMAD4 (Abcam, Cambridge, MA, USA) and phospho-SMAD3 (Cell Signaling) antibodies (see Supplementary Material).
I.p. ovarian xenograft model
In all, 3 Â 10 6 SKOV3 cells stably transfected with AS-TG2 or pCDNA3.1 vector, were injected i.p. in 7-8 weeks old female nude mice from Harlan (Indianapolis, IN, USA). Treatment with SD208 (60 mg/kg daily) or vehicle control began 1 week after i.p. implantation via gavage and was continued for 5 weeks. Each of the four experimental groups consisted of four animals. Six weeks after i.p. injection, mice were euthanized, tumors were harvested, measured bi-dimensionally if 45 mm and peritoneal implants were counted. Experiments were approved by the IU Animal Care and Use Committee.
Statistical analysis
The Student's t-test compared quantitative data between groups, Fisher's exact test compared immunohistochemistry staining for TG2 and pSMAD3. Po0.05 was significant.
